Literature DB >> 17415440

In vivo anticancer activity of lysates from trypanosoma cruzi of different genetic groups.

Zetsegsaikhan Batmonkh1, V D Kallinikova, L V Pakhorukova, E G Kravtsov, L P Karpenko, M V Dalin.   

Abstract

Lyzed epimastigotes of Trypanosoma cruzi clones P209-1, Gamba1, Sp104-1, MASu, Y7/1, MN12, Cl-Brener, 86/2036, Y7/2-1 inhibit the growth of Ehrlich adenocarcinoma in mice. the tumor decreased 1.5-3 times after 12 daily injections of lysates from 15 million epimastigotes. The protective effect progressed after the injections were discontinued and depended on the dose and lysate producer clone. Trypanosoma lysates in the studied doses were nontoxic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17415440     DOI: 10.1007/s10517-006-0395-6

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  4 in total

1.  Common antigens between hydatid cyst and cancers.

Authors:  Shima Daneshpour; Mehran Bahadoran; Seyed Hossein Hejazi; Abas Ali Eskandarian; Mehdi Mahmoudzadeh; Hossein Yousofi Darani
Journal:  Adv Biomed Res       Date:  2016-01-29

2.  Immunization with Hydatid Cyst Wall Antigens Can Inhibit Breast Cancer through Changes in Serum Levels of Th1/Th2 Cytokines.

Authors:  Mahshid Shakibapour; Behrokh Shojaie; Hossein Yousofi Darani
Journal:  Int J Prev Med       Date:  2020-12-11

3.  In vitro anti-gastrointestinal cancer activity of Toxocara canis -derived peptide: Analyzing the expression level of factors related to cell proliferation and tumor growth.

Authors:  Saeed Bahadory; Javid Sadraei; Mohammad Zibaei; Majid Pirestani; Abdolhossein Dalimi
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

4.  Does native Trypanosoma cruzi calreticulin mediate growth inhibition of a mammary tumor during infection?

Authors:  Paula Abello-Cáceres; Javier Pizarro-Bauerle; Carlos Rosas; Ismael Maldonado; Lorena Aguilar-Guzmán; Carlos González; Galia Ramírez; Jorge Ferreira; Arturo Ferreira
Journal:  BMC Cancer       Date:  2016-09-13       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.